Lung Cancer Trials Ask AI to find trials
Active Not RecruitingNot applicableNCT04305613
Official study title

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy

Study summary

This observational cohort will evaluate the cardiovascular effects of chemoradiation used to treat locally advanced, non-small cell lung cancer. Patients will be enrolled prior to the start of therapy and followed during and for at least 2 years after therapy with echocardiograms, nuclear stress tests, blood sampling, and quality of life surveys.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedChemoradiation

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable · Locally advanced

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 5, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Not applicable

Observational

Where is it offered?8 U.S. locations

Locations may change over time.

Who runs it?Abramson Cancer Center at Penn Medicine

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Abramson Cancer Center at Penn Medicine
Interventions being studied
Other: Chemoradiation
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Early-stage or resectable→Locally advanced→
Treatment approach
Radiation therapy→
Study topics
Survivorship and quality of life→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • At least 18 years of age
  • Histologically confirmed or clinically diagnosed non-small cell lung cancer where the plan is for definitive treatment that includes radiation
  • Able to give written informed consent
Reasons someone may not be able to joinExclusion criteria
  • Pregnant or breast-feeding
  • Prior treatment with anthracyclines
  • Radiation treatment not expected to involve any heart exposure as determined by treating provider
  • ECOG performance status greater than 2
  • Vulnerable patients, including pregnant women and prisoners
  • Contraindication to rest/vasodilator stress PET/CT, including: asthma with ongoing wheezing at time of enrollment; known Mobitz Type II AV block, 3rd degree AV block, or sick sinus syndrom, without a pacemaker; systolic blood pressure less than 90mmHg; known hypersensitivity to Regadenoson and adenosine; profound sinus bradycardia (heart rate less than 40bpm).

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of AlabamaBirmingham, Alabama
  • The Brigham and Women's HospitalBoston, Massachusetts
  • Washington University School of MedicineSt Louis, Missouri
  • Rutger's University / Cancer Institute of New JerseyNew Brunswick, New Jersey
  • Montefiore Medical CenterThe Bronx, New York
  • Lancaster General HospitalLancaster, Pennsylvania
  • Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, Pennsylvania
  • Chester County HospitalWest Chester, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 5, 2026. Always confirm current availability with the study team.

View original record ↗